Medicaid GLP-1 coverage in Kansas, 2026.

Kansas Medicaid covers Wegovy for weight loss, with limits.

What Kansas Medicaid actually covers for Wegovy, Zepbound, Ozempic and Mounjaro. Most state Medicaid programs still exclude weight-loss-indication GLP-1, but the diabetes path is covered nearly everywhere with prior authorization (your doctor asks the plan to approve it first). Here is the current 2026 reality for Kansas.

Coverage summary

IndicationCoverage
Wegovy (weight loss)Limited
Zepbound (weight loss)No
Ozempic / Mounjaro (type 2 diabetes)Yes
Compounded semaglutide / tirzepatideNo

Prior-authorization criteria

These rules come from the state preferred drug list (PDL), the list of drugs Kansas Medicaid has agreed to pay for.

CriterionValue
PA burdenMedium
BMI threshold (weight-loss path)BMI 40+
Comorbidity requiredYes
Last PDL update reviewed2025-Q3

What this means in practice

KanCare covers Wegovy, Zepbound and Saxenda for weight management with prior authorization (KDHE anti-obesity form, revised June 2025): BMI 40 or higher with a weight-related comorbidity checklist, or Wegovy at BMI 27 or higher with established cardiovascular disease, after 3 months of documented lifestyle changes. Applies to fee-for-service and all three KanCare plans.

Managed-care organizations in Kansas (3 contracted)

Kansas Medicaid contracts with the following managed-care organizations (MCOs), the private health plans the state pays to run day-to-day Medicaid coverage. MCO formularies must meet or exceed the state PDL but can layer in additional criteria. Verify your assigned MCO's most recent PA policy before submitting.

  • Aetna Better Health of Kansas
  • Sunflower Health Plan (Centene)
  • UnitedHealthcare Community Plan

Cash-pay alternatives if Medicaid does not cover you

Cash-pay compounded GLP-1 is the practical fallback. See /best/cheapest/.

If you end up paying cash, the GLP-1 cost guide breaks down what every legitimate path actually costs at maintenance dose, from the $149-a-month compounded floor to branded manufacturer-direct pricing. For ranked cash-pay options, see programs ranked by price and programs under $150 a month. For manufacturer patient-assistance routes that bypass insurance entirely, see every cost-reduction pathway in 2026. For manufacturer savings cards and the Medicare Bridge, see the GLP-1 coupons and savings guide.

Take it to your prescriber: PA letter library

If you qualify under one of the covered indications above, the prior-authorization route is the cheapest path. We maintain a PA letter library with templates for Aetna, Cigna, UnitedHealthcare, Anthem BCBS, Kaiser, Humana, Tricare, FEHB and Medicare Advantage, cross-indexed against six qualifying clinical pictures. Each template cites the plan's policy document, the qualifying ICD-10 codes and the registration-trial evidence.

If you have type 2 diabetes plus chronic kidney disease and established cardiovascular disease, the triple-indication evidence stack (FLOW + SELECT + SUSTAIN-6) is the strongest PA path in any state.

If your PA is denied, the appeal letter library has denial-specific templates. For the commercial and Medicare coverage paths, see the GLP-1 insurance guide.

Kansas Medicaid GLP-1 FAQ

Does Kansas Medicaid cover Wegovy for weight loss?
It depends. Coverage of Wegovy for weight loss under Kansas Medicaid is limited and can vary by managed-care plan. Prior authorization is required. Check your specific plan's drug list. Last state review: 2025-Q3.
Does Kansas Medicaid cover Zepbound for weight loss?
No. Kansas Medicaid does not cover Zepbound for the weight-loss indication as of the 2025-Q3 preferred drug list review. If you have type 2 diabetes, Mounjaro (tirzepatide, the same molecule as Zepbound) may be covered with prior authorization under the diabetes pathway.
Does Kansas Medicaid cover Ozempic or Mounjaro for diabetes?
Yes. Kansas Medicaid covers Ozempic and Mounjaro for type 2 diabetes with prior authorization, usually after a trial of metformin. The diabetes pathway does not carry the BMI threshold that applies to the weight-loss pathway.
What if Kansas Medicaid does not cover my GLP-1?
If your GLP-1 is not covered, the practical options are manufacturer patient-assistance programs (NovoCare for Wegovy, the Lilly savings programs for Zepbound), the diabetes pathway if you have type 2 diabetes, or cash-pay compounded semaglutide starting around $149 a month. Cash-pay compounded GLP-1 is the practical fallback. See /best/cheapest/. If you were denied, the appeal letter library has denial-specific templates.

Other state Medicaid pages

See the full 51-state coverage table for the side-by-side view across every US state.

How we built this page

Compiled from each state Medicaid's published preferred drug list, PA criteria and PDL committee minutes. State Medicaid programs are not federally required to cover obesity drugs; the diabetes indication is covered nearly everywhere with PA. State-level data is point-in-time and shifts each PDL cycle. Always verify with your state Medicaid plan before relying on this page.

Last updated: 2026-07-13. We check each state Medicaid PDL and PA criteria quarterly. If you have recently had a different experience with Kansas Medicaid, email hello@glpchart.com with the details and we will check it.

Why you can trust GLP ChartSame scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.